This segment focuses on the development, manufacturing, and commercialization of MaxCyte's core technology platforms. These include the ExPERT series of instruments (STX, VLX, GT) and associated consumables, which utilize flow electroporation technology for non-viral cell engineering. Research and development activities are centered on improving the efficiency, scalability, and versatility of these platforms to support a wide range of cell-based applications. The technologies are used in various therapeutic areas, including oncology, immunology, and regenerative medicine, enabling the development of cell therapies, gene therapies, and other advanced therapeutics. The patient impact is significant, as these technologies facilitate the creation of novel treatments for diseases with high unmet medical needs. MaxCyte's market positioning is strong due to its established technology and partnerships with leading biopharmaceutical companies. Future opportunities include expanding the applications of its platforms and entering new therapeutic areas. Regulatory and clinical aspects are crucial, as the company works to ensure its technologies meet the stringent requirements for clinical use. Partnerships and collaborations with companies like Allogene Therapeutics, Inc. and Ori Biotech are key to driving innovation and market penetration.

This segment encompasses MaxCyte's activities related to the development of cell-based therapies, including its proprietary CARMA technology for the development of non-viral, human messenger RNA-based, chimeric antigen receptor or T-cell receptor redirected immune cell therapies. Research and development efforts focus on optimizing CARMA technology and exploring its application in various cancer types. The segment also includes strategic partnerships and collaborations with biopharmaceutical companies to advance cell therapy programs. The therapeutic areas covered include oncology and potentially other areas where cell-based therapies can provide significant clinical benefits. The patient impact is substantial, as these therapies offer the potential for more effective and targeted treatments for cancer and other diseases. MaxCyte's market positioning is enhanced by its partnerships and its focus on innovative cell engineering approaches. Future opportunities include expanding the pipeline of therapeutic candidates and securing additional partnerships. Regulatory and clinical aspects are critical, as the company navigates the complex regulatory landscape for cell therapies. Collaborations with companies like Allogene Therapeutics, Inc. are essential for clinical development and commercialization.